Filing Flows › Gyre Therapeutics (GYRE) › Q3 2026 › vs Q3 2025
Gyre Therapeutics (GYRE) Q3 2026 vs Q3 2025 (year over year)
Gyre Therapeutics's revenue rose $240K (+0.7%) from $32.7M in Q3 2025 to $32.9M in Q3 2026. The biggest changes: Gyre Pharmaceuticals +$1.9M (+6%); Gyre −$1.6M (-76%).
Gyre Therapeutics, Q3 2026: revenue $32.9M (+0.7% year over year), operating margin -4.6%, net loss $2.5M, operating cash flow −$4.0M. The chart draws each line against Q3 2025, the increases inside each band.
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Gyre Pharmaceuticals | $32.4M | $30.6M | $1.9M | +6% |
| Gyre | $508K | $2.1M | −$1.6M | -76% |
| Revenue | $32.9M | $32.7M | $240K | +0.7% |
| Net loss | $2.5M | −$1.9M | $4.4M | — |
| Costs & expenses | $35.4M | $33.7M | $1.7M | +5% |
| Operating costs | $34.5M | $31.2M | $3.3M | +10% |
| Interest & other, net | $225K | −$1.0M | $1.3M | — |
| Income tax | $733K | $593K | $140K | +24% |
| SG&A | $8.9M | $6.4M | $2.5M | +39% |
| Other operating costs | $23.6M | $13.2M | $10.4M | +78% |
| Operating cash sources | $6.2M | $4.7M | $1.4M | +30% |
| Depreciation & amortization | $467K | $828K | −$361K | -44% |
| Share-based compensation | $1.7M | $1.3M | $400K | +30% |
| Cash used in operations | $4.0M | $2.6M | $1.4M | +54% |
| Net loss absorbed | $2.5M | −$1.9M | $4.4M | — |
| Working capital & other | $3.7M | $6.7M | −$3.0M | -44% |
Questions
How much did Gyre Therapeutics's revenue grow year over year in Q3 2026?
Gyre Therapeutics's revenue rose $240K (+0.7%) from $32.7M in Q3 2025 to $32.9M in Q3 2026.
What drove Gyre Therapeutics's revenue change in Q3 2026?
Gyre Pharmaceuticals +$1.9M (+6%); Gyre −$1.6M (-76%).